Synthesis of Pyridazinone Derivatives Substituted with Methoxy with Phenyl Hydrazine and In Silico Test of Anticancer Activity

Authors

  • Winda Permata Zulmy Department of Chemistry, Faculty of Mathematics and Natural Sciences (FMIPA), Riau University, Pekanbaru, Indonesia
  • Putri Mar Atus Sholihah Department of Chemistry, Faculty of Mathematics and Natural Sciences (FMIPA), Riau University, Pekanbaru, Indonesia
  • Hilwan Yuda Teruna Department of Chemistry, Faculty of Mathematics and Natural Sciences (FMIPA), Riau University, Pekanbaru, Indonesia
  • Jasril Department of Chemistry, Faculty of Mathematics and Natural Sciences (FMIPA), Riau University, Pekanbaru, Indonesia

DOI:

https://doi.org/10.25077/jrk.v16i2.809

Keywords:

Pyridazinone, Phenyl hydrazine, in silico, Breast cancer, Estrogen receptor α

Abstract

The synthesis of pyridazinone derivatives has gained increasing attention due to their diverse biological activities, particularly as anticancer agents. In this study, novel pyridazinone derivatives substituted with methoxy groups and phenyl hydrazine were synthesized through a multi-step reaction pathway, starting from methoxyacetophenone and glyoxylic acid, followed by cyclization and substitution reactions to yield the target compound 7-(2-methoxyphenyl)-2H-pyridazino[6,1-c][1,2,4]triazine-3(4H)-one. The synthesized compounds were characterized by melting point, TLC, HPLC, UV-Vis, FTIR, NMR, and MS analyses, confirming the expected structures. In silico evaluation was performed using molecular docking against estrogen receptor α (ERα) kinase domain (PDB ID: 1T46), a key protein in breast cancer progression. The docking results showed that the synthesized compounds exhibited strong binding affinities, with compound 8 displaying a binding free energy of –9.1971 kcal/mol and stable interactions with residues Cys673, Leu799, and Phe811. These values were superior compared to the natural ligand and comparable to the reference drug doxorubicin, indicating significant anticancer potential. The results suggest that structural modification of pyridazinone with methoxy and phenyl hydrazine substituents enhances its cytotoxic activity, making it a promising candidate for further development as an anticancer agent.

References

1. Singh, J., Kumar, V., Silakari, P., Kumar, S. 2023. Pyridazinones: A versatile scaffold in the development of potential target-based novel anticancer agents. In Journal of Heterocyclic Chemistry. 60 : 6.

2. Merde, İ.B., Önel, G.T., Akkoç, S., Karaköy, Z., Türkmenoğlu, B. 2023. Focusing on new piperazinyl-methyl-3(2H)pyridazinone based derivatives: Design, synthesis, Anticancer activity and Computational studies. ChemistrySelect. 8(25). https://doi.org/10.1002/slct.202300910.

3. Asif, M. 2019. A review on pyridazinone ring containing various cardioactive agents. Journal of chemical.

4. Partap, S., Akhtar, M.J., Yar, M.S., Hassan, M.Z., Siddiqui, A.A. 2018. Pyridazinone hybrids: design, synthesis and evaluation as potential anticonvulsant agents. Bioorganic Chemistry. 77: 74–83.

5. Tiryaki, D., Sukuroglu, M., Dogruer, D.S., Akkol, E., Sahin, M.F. 2013. Synthesis of some new 2,6-disubstituted-3(2H)-pyridazinone derivatives and investigation of their analgesic, anti-inflammatory and antimicrobial activities. Medicinal Chemistry Research. 22 (6): 2553–2560.

6. Siddiqui, A.A., Mishra, R., Shaharyar, M. 2010. Synthesis, characterization and antihypertensive activity of pyridazinone derivatives. European Journal of Medicinal Chemistry. 45 (6): 2283–2290.

7. Ritchie, T.J., Macdonald, S.J., Peace, S. 2012. The developability of heteroaromatic and heteroaliphatic rings–do some have a better pedigree as potential drug. Med Chem Comm. 3 : 1062–9.

8. Jaballah, M.Y., Serya, R.T., & Abouzid, K. 2017. Pyridazine based scaffolds as privileged structures in anti-cancer therapy. Drug Res (Stuttg), 67(3): 138–48.

9. Merde, İ.B., Önel, G.T., Akkoç, S., Karaköy, Z., & Türkmenoğlu, B. 2023. Focusing on new piperazinyl-methyl-3(2H)pyridazinone based derivatives: Design, synthesis, Anticancer activity and Computational studies. ChemistrySelect, 8(25): e202300910.

10. Merde, İ.B., Önel, G.T., Akkoç, S., Karaköy, Z., & Türkmenoğlu, B. 2023. Focusing on new piperazinyl-methyl-3(2H)pyridazinone based derivatives: Design, synthesis, Anticancer activity and Computational studies. ChemistrySelect, 8(25): e202300910.

11. Blume-Jensen, P., & Hunter, T. (2001). Oncogenic kinase signalling. Nature, 411, 355–365.

12. Wu, X., et al. (2020). Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors. Acta Pharmaceutica Sinica B, 11(3), 781–794.

13. Ali, S., Rasool, M., Chaoudhry, H., Pushparaj, P. N., Jha, P., Hafiz, A., & Jamal, M.S. 2016. Molecular mechanisms and mode of tamoxifen resistance in breast cancer. Bioinformation, 12(3): 135–139.

14. Chung, C. (2017). "Pyridazinone Synthesis and Reaction Mechanisms." Journal of Medicinal Chemistry, 60(1): 23–38.

15. Özdemir, A., Demirci, F., Abu Mohsen, U., & Kaplancıklı, Z. A. (2013). Synthesis and antifungal activity of new hydrazide derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 28(6), 1211–1216.

16. Adelusi, T. I., Oyedele, A. K., Boyenle, I. D., Ogunlana, A. T., Adeyemi, R. O., Ukachi, C. D., Idris, M. O., Olaoba, O. T., Adedotun, I. O., Kolawole, O. E., Xiaoxing, Y., Abdul-Hammed, M. (2022). Molecular modeling in drug discovery. Informatics in Medicine Unlocked, 29, 100880.

17. N. Frimayanti, M. Yaeghoobi, H. Namavar, M. C. Utari, M. Djohari, and C. O. Laia, “In silico analysis approach for screening new agents for breast cancer inhibitors based on 1,5-benzothiazepine,” Pharm. Sci. Asia, vol. 49, no. 5, 2022, doi: 10.29090/psa.2022.05.22.001.

Downloads

Published

2025-09-30

How to Cite

Zulmy, W. P., Sholihah, P. M. A., Yuda Teruna, H., & Jasril. (2025). Synthesis of Pyridazinone Derivatives Substituted with Methoxy with Phenyl Hydrazine and In Silico Test of Anticancer Activity. Jurnal Riset Kimia, 16(2), 27–38. https://doi.org/10.25077/jrk.v16i2.809

Issue

Vol. 16 No. 2 (2025): September

Section

Articles

Citation Check

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Please find the rights and licenses in Jurnal Riset Kimia (J. Ris. Kim). By submitting the article/manuscript of the article, the author(s) agree with this policy. No specific document sign-off is required.

1. License

The use the article will be governed by the Creative Commons Attribution license as currently displayed on Creative Commons Attribution 4.0 International License. 

2. Author(s)' Warranties

The author warrants that the article is original, written by stated author(s), has not been published before, contains no unlawful statements, does not infringe the rights of others, is subject to copyright that is vested exclusively in the author and free of any third party rights, and that any necessary written permissions to quote from other sources have been obtained by the author(s).

3. User Rights

Under the Creative Commons license, the journal permits users to copy, distribute, and display the material for any purpose. Users will also need to attribute authors and J. Ris. Kim on distributing works in the journal and other media of publications.

4. Rights of Authors

Authors retain all their rights to the published works, such as (but not limited to) the following rights;

  • Copyright and other proprietary rights relating to the article, such as patent rights,
  • The right to use the substance of the article in own future works, including lectures and books,
  • The right to reproduce the article for own purposes,
  • The right to self-archive the article,
  • The right to enter into separate, additional contractual arrangements for the non-exclusive distribution of the article's published version (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

5. Co-Authorship

If the article was jointly prepared by more than one author, any authors submitting the manuscript warrants that he/she has been authorized by all co-authors to be agreed on this copyright and license notice (agreement) on their behalf, and agrees to inform his/her co-authors of the terms of this policy. J. Ris. Kim will not be held liable for anything that may arise due to the author(s) internal dispute. J. Ris. Kim will only communicate with the corresponding author.

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.